View in your browser



INNOVATION AND COMMERCIALIZATION

OHSU INNOVATES

March 8, 2023

Leadership Message


This month we celebrate the 2023 OHSU Innovation Awardees. These scientists are among those at OHSU successfully innovating and partnering to develop new healthcare solutions by collaborating closely with the OHSU Innovates network. We'll be honoring them and others at the 2023 OHSU Innovation Awards event on March 22 at the Robertson Life Sciences Building on the South Waterfront. See the details below and join us for a networking happy hour — we're looking forward to celebrating in person again.

Below, you'll also find a few of the recent successes of OHSU researchers and OHSU startups — these represent just a few of the many contributions OHSU researchers are making to better health and well-being in Oregon and beyond.

Travis Cook, M.S., M.B.A., CLP Senior Director, Technology Transfer

Aditi Martin, Ph.D.

Senior Director, Collaborations and Entrepreneurship



Congratulations to the 2023 OHSU Innovation Awardees!

Beth Habecker, Ph.D., Yali Jia, Ph.D., Matthew Rames, Ph.D., and Timur Tsintsadze, Ph.D., have been named the 2023 OHSU Innovation Awardees by the OHSU Innovates community. In addition, Erik Tucker, Ph.D., has been elected as a Fellow of the National Academy of Inventors. This group has demonstrated an outstanding passion for innovation and collaboration and each works closely with the OHSU Innovates network. More details about the awardees and their innovative research can be found in the 2023 OHSU Innovation Awards announcement.

Come celebrate these awardees and enjoy a networking happy hour with complimentary drinks and hors d'oeuvres at the in-person 2023 Innovation Awards event.

2023 OHSU Innovation Awards - event details

WHEN	Wednesday, March 22 4-7 p.m. PDT
WHERE	Robertson Life Sciences Building, Room 3A001 2730 S Moody Ave, Portland, OR 97201
WHO	Open to all OHSU members, invited regional partners and OHSU Innovates sponsors

Featured News

Driven by OHSU research, FDA approves new drug to prevent hearing loss in children with cancer

OHSU Innovates shared the news in November that OHSU startup Fennec Pharmaceuticals received FDA approval for PEDMARK®, a therapy to reduce the risk of treatment-induced hearing loss among children who receive the common chemotherapy drug cisplatin. Read more about the OHSU research behind the drug and the patients PEDMARK could serve in the recent OHSU news article.

Artificial intelligence, diabetes experts combine forces for blood sugar management study

To help the estimated 1.45 million Americans living with type 1 diabetes better manage their blood sugar levels, OHSU is combining the power of an artificial intelligence-driven smartphone app with the support of human experts. Leading the project are OHSU biomedical engineer Peter G. Jacobs, Ph.D., and OHSU endocrinologist Leah M. Wilson, M.D., who are organizing a randomized clinical trial to evaluate the impact of using their enhanced app in concert with diabetes education specialists. Read more about the new study in the OHSU news article.

PDX Pharma drug candidate accepted into the Nanotechnology characterization lab's Collaboration and Characterization Program

The Nanotechnology Characterization Laboratory announced that it has accepted drug candidate ARAC-02, developed by OHSU startup company PDX Pharmaceuticals, into the NCL's Assay Cascade Characterization

Program. ARAC-02 targets PD-L1, PLK1 and TLR9, and has the ability to simultaneously kill cancer while also inducing a potent anti-tumor immune response. Read more in the press release.

OHSU researchers identify promising nextgeneration cancer treatment

Researchers at OHSU have uncovered a new class of PARP-1 inhibitors with unique and powerful anticancer properties that could make them more widely effective. The study was co-authored by Michael Cohen, Ph.D., associate professor of chemical physiology and biochemistry in the OHSU School of Medicine, and M.D./Ph.D. student Moriah Arnold. Read more about this recent work on PARP-1 inhibitors in the OHSU news article.

OHSU physician-scientist elected to National Academy of Engineering

Congratulations to David Huang, M.D., Ph.D., professor of ophthalmology at the OHSU Casey Eye Institute on his recent election to the National Academy of Engineering. Huang was recognized for co-inventing a medical imaging technology called optical coherence tomography, which is commonly used to diagnose and guide treatment for the leading causes of blindness. Read more about this honor in the OHSU news article.

Announcements



Get involved with the Angel Oregon Life and Bioscience education and investment series

Angel Oregon Life and Bioscience (AOBIO) is the premier PNW life and bioscience investment program, hosted by Oregon Entrepreneurs Network in partnership with Oregon Bioscience Association, Oregon Bioscience Incubator and OHSU Innovates.

The 2023 AOBIO education series kicked off last month, but there are still several ways to get involved!

- Life science startups: Are you interested in the education series? You can still register and get access to recordings of sessions that have taken place and attend the final session on March 15.
- Life science startups: Are you interested in investment money from AOBIO? Register by March 15 for a chance to win up to \$300,000.
- Investors: Are you interested joining this collective angel investment opportunity? Commit by March 23.
- Life science enthusiasts: Attend the AOBIO finale to watch the finalists pitch and network with the regional innovation and entrepreneur community.

Find out more at the **AOBIO** website.

Applications are open for the Life Science Innovation Northwest pitch event and poster presentations

The region's largest life science showcase, Life Science Innovation Northwest 2023, is a great place to network and share your venture. The conference includes presentations by top regional companies, panels and plenty of opportunities for networking. Applications are currently open for poster presentations as well as the fast pitch investment opportunity.

Fast Pitch

Move over Shark Tank! Ten life science early-stage companies compete on the main stage for a \$5,000 judges-pick prize and a \$1,000 audience-pick prize. Applications are due April 5 and interested parties can find more details in the Fast Pitch application flyer.

Poster presentations

Poster presentations are displayed throughout the duration of the conference. Share scientific results, business plans, executive summaries or team bios. Companies, nonprofits, and student groups are welcome to apply - deadline is April 5. More details can be found in the poster presentation application flyer.

Portland Incubator Experiment (PIE) applications close March 14

PIE is a product-focused startup accelerator for early stage SaaS, mobile, and tech-enabled companies designed to connect participants with peers, mentors, investors, and other critical connections. For the 2023 class, PIE will be selecting a cohort of startups located in Portland, Oregon, that have at least one Black person, Indigenous person, or another Person of Color (BIPOC) serving as a founder or cofounder. Applications are due March 14 and more information can be found on the PIE website.

Funding Opportunities

Each week, OHSU Research Development compiles a list of funding opportunities from internal sources, the government and private foundations. The list is published every Thursday. A .pdf of the current list is also available.

Upcoming Events

OHSU Innovation Day - May 4

Innovation Day 2023 will be held virtually on May 4, as a part of OHSU 2023 Research Week. Save the date to learn more about how pioneering research at OHSU is brought to market to benefit the global community. Innovation day panels will also cover topics of how to overcome obstacles in getting your idea to market and a commercialization focused career panel. Visit the OHSU 2023 Research Week webpage for more information on the full week's schedule.

Other upcoming events

March 14	Bio on the Rocks
March 15	Life Science Washington Institute: Venture Investment & Partnering Forum
March 15	Partnering with the NIH Beyond SBIR Grants
April 6-7	Science Talk '23
April 25- 26	Life Science Innovation Northwest
May 1-5	OHSU 2023 Research Week
May 3	Portland Clinical Research Professional Conference

June 5-8

BIO 2023: Showcase Your Company at the Oregon
Pavilion

Technologies

Featured technologies available for licensing

A selection of OHSU-developed technologies available for licensing to industry partners. For more technologies visit the OHSU Technology Portal.

OHSU 2346 - Metabolic activity diffusion imaging, or MADI, technology provides significantly higher resolution than existing approaches such as PET, and does not require exogeneous contrast agents.

OHSU 2936 - DailyDose smart phone app provides real-time dosing advice and weekly insulin dose adjustments to improve glucose management in patients with type 1 diabetes using daily insulin injections.

OHSU 2985 - Label-free fluorescent sensing of protease activity technology offers lower background noise, simplified label-free synthesis, compatibility with any protease of interest and utility for translational research and clinical diagnostics.

OHSU 2939 - Photoactivatable modulation of antibody binding technology has the potential to increase antibody specificity and reduce unwanted off-target effects and does not require genetic modification of the antibody sequence.

Sponsors

Thank you to our current sponsors for their support of OHSU Innovates.



Questions? Contact us at innovates@ohsu.edu.

This monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, Oregon Clinical and Translational Research Institute, School of Medicine and the Knight Cancer Institute.

©2023 OHSU

This email was sent by OHSU 3181 S.W. Sam Jackson Park Rd. Portland, OR, 97239, US

This email was sent to: kubat@ohsu.edu
Unsubscribe | Manage subscriptions | Update profile
OHSU email terms of service | OHSU privacy policy